CTRI/2023/11/060006Not yet recruitingPhase 4
Antifactor Xa levels vs. activated partial thromboplastin time (aPTT) for monitoring Low-molecular weight heparin (LMWH) Residual Activity In Patients Presenting For Elective Surgery:A Comparative Study. - NI
Trial Snapshot
- Phase
- Phase 4
- Status
- Not yet recruiting
- Sponsor
- AIIMS, Bhopal
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
Inclusion Criteria
- •1)To be on prophylactic dose of Inj. Enoxaparin at the time of presentation for elective surgery
- •2)Must be able to accurately report the timing of their last dose and the administered dosage.
- •3)Patients must also be between the ages of 18-80 years of age
- •4) Must be able to give written consent to participate.
Exclusion Criteria
- •1) Factors known to interfere with aPTT monitoring such as lupus anticoagulant disease, clotting factor deficiencies (factor V, VIII, IX, X, XI, XII and von Willebrand disease), severe liver disease, acquired vitamin K deficiency, antithrombin (AT) III deficiency, elevated levels of clotting factors, pregnancy and increased factor VIII level.
- •2) Patients who are receiving enoxaparin as a bridge from another anti-Xa inhibiting medication will be excluded as this could unpredictably affect the results of anti-Xa testing. These medications include: Apixaban, Edoxaban, Fondaparinux, and Xarelto.
Investigators
Similar Trials
Completed
Not Applicable
Comparative anti-Factor Xa activity between standard dose and Japanese dose of rivaroxaban in Thai patients with non-valvular atrial fibrillatioon-valvular Atrial Fibrillation.-Non-valvular Atrial Fibrillationanti-XA activityRivaroxaban standard doseRivaroxaban Japanese doseTCTR20181104002Faculty of Medicine, Chiang Mai University60
Active, not recruiting
Phase 1
During atrial fibrillation catheter ablation procedure treatment with anticoagulant drugs is necessary in order to prevent blood clotting and thereby decrease the risk of procedure related strokes. In this study two different types of anticoagulant drugs are being compared during and after the atrial fibrillation catheter ablation procedure: the novel direct factor Xa inhibitor apixaban and any of the standard vitamin K antagonists.Atrial fibrillation catheter ablationMedDRA version: 19.1Level: PTClassification code 10003658Term: Atrial fibrillationSystem Organ Class: 10007541 - Cardiac disordersMedDRA version: 19.1Level: LLTClassification code 10071667Term: Persistent atrial fibrillationSystem Organ Class: 10007541 - Cardiac disordersMedDRA version: 19.1Level: LLTClassification code 10003661Term: Atrial fibrillation paroxysmalSystem Organ Class: 10007541 - Cardiac disordersMedDRA version: 19.1Level: LLTClassification code 10066582Term: Recurrent atrial fibrillationSystem Organ Class: 10007541 - Cardiac disordersEUCTR2014-002442-45-ATKompetenznetz Vorhofflimmern e.V. (AFNET) [Atrial Fibrillation NETwork]650
Active, not recruiting
Phase 1
During atrial fibrillation catheter ablation procedure treatment with anticoagulant drugs is necessary in order to prevent blood clotting and thereby decrease the risk of procedure related strokes. In this study two different types of anticoagulant drugs are being compared during and after the atrial fibrillation catheter ablation procedure: the novel direct factor Xa inhibitor apixaban and any of the standard vitamin K antagonist.EUCTR2014-002442-45-DEKompetenznetz Vorhofflimmern e.V. [Atrial Fibrillation NETwork (AFNET)]650
Active, not recruiting
Phase 1
During atrial fibrillation catheter ablation procedure treatment with anticoagulant drugs is necessary in order to prevent blood clotting and thereby decrease the risk of procedure related strokes. In this study two different types of anticoagulant drugs are being compared during and after the atrial fibrillation catheter ablation procedure: the novel direct factor Xa inhibitor apixaban and any of the standard vitamin K antagonists.Atrial fibrillation catheter ablationMedDRA version: 18.0Level: PTClassification code 10003658Term: Atrial fibrillationSystem Organ Class: 10007541 - Cardiac disordersMedDRA version: 18.0Level: LLTClassification code 10071667Term: Persistent atrial fibrillationSystem Organ Class: 10007541 - Cardiac disordersMedDRA version: 18.0Level: LLTClassification code 10066582Term: Recurrent atrial fibrillationSystem Organ Class: 10007541 - Cardiac disordersMedDRA version: 18.0Level: LLTClassification code 10003661Term: Atrial fibrillation paroxysmalSystem Organ Class: 10007541 - Cardiac disordersEUCTR2014-002442-45-ESThe Kompetenznetz Vorhofflimmern e.V. [German Atrial Fibrillation Competence Network association (AFNET e.V.)]650
Active, not recruiting
Phase 1
During atrial fibrillation catheter ablation procedure treatment with anticoagulant drugs is necessary in order to prevent blood clotting and thereby decrease the risk of procedure related strokes. In this study two different types of anticoagulant drugs are being compared during and after the atrial fibrillation catheter ablation procedure: the novel direct factor Xa inhibitor apixaban and any of the standard vitamin K antagonist.EUCTR2014-002442-45-BEThe Kompetenznetz Vorhofflimmern e.V. [German Atrial Fibrillation Competence Network association (AFNET e.V.)]650